【Morgan Stanley】【20220909】Regeneron Pharmaceuticals Inc. High-dose Eylea derisked; Survey points to robust uptake; Upgrade to Overweight-52页

Morgan Stanley 公共管理社会组织 2022年 PDF 3.33 MB

market forecast High-dose Eylea Regeneron Pharmaceuticals biotechnology Stock Rating